Another drug company in the crosshairs of Congress

Another pharmaceutical company is being targeted by lawmakers over drug pricing.

Shares of Medivation tumbled more than 6 percent in premarket trading Tuesday after a group of lawmakers opened a campaign to potentially lower the price of its prostate cancer drug.

Reps. Lloyd Doggett and Peter Welch and Sen. Bernie Sanders urged the Department of Health and Human Services and the National Institutes of Health to step in to cut for the drug Xtandi, saying it costs four times more in the U.S. than it does outside the country.

They are asking for public hearings over the drug, which they say was developed at the University of California, Los Angeles, through taxpayer-supported research grants. It is sold by Japanese drug maker Astellas Pharma.

The want the NIH to consider overriding Xtandi's patent in hopes that the price of the will fall.

Medivation is just the latest drugmaker to find itself in the crosshairs of Congress.

The CEO of beleaguered Valeant Pharmaceuticals Inc. was subpoenaed Monday to appear before a congressional committee, its third hearing since December, to determine the reasoning behind the skyrocketing price for drugs.

Executives at Valeant, Turing Pharmaceuticals and several other drugmakers have been buying up rights to those old drugs and then jacking up prices many times over what patients had paid for years.

Executives of the companies have been invited or subpoenaed to testify at hearings on the issue held by multiple Congressional committees.

Medivation Inc., based in San Francisco, did not immediately respond to a request for comment. Its stock dropped $2.55 to $38.70 before the market open.

© 2016 The Associated Press. All rights reserved.

Citation: Another drug company in the crosshairs of Congress (2016, March 29) retrieved 22 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Senate panel investigates drug price hikes


Feedback to editors